Advanced search
1 file | 1.21 MB

Pharmacokinetics and tissue transport of intraperitoneal chemotherapy

Nick Lagast (UGent) , Charlotte Carlier (UGent) and Wim Ceelen (UGent)
Author
Organization
Abstract
The presence of a peritoneal barrier results in a pharmacokinetic advantage associated with intraperitoneal (IP) delivery of anticancer drugs. The anticancer efficacy of IP chemotherapy depends, however, on its ability to penetrate the tumor stroma. Tumor tissue transport is governed by diffusion and convection and is affected by numerous physical, biological, and pharmaceutical variables. From preclinical and clinical studies, it appears that tissue penetration after IP chemotherapy delivery is very limited. Several approaches are studied to improve tissue penetration of small molecular and macromolecular anticancer drugs after IP instillation.
Keywords
Pharmacokinetics, Chemotherapy, HIPEC, Carcinomatosis, INTERSTITIAL FLUID PRESSURE, PANCREATIC DUCTAL ADENOCARCINOMA, HUMAN OSTEOSARCOMA XENOGRAFTS, HEDGEHOG PATHWAY INHIBITOR, OVARIAN-CANCER, PERITONEAL CARCINOMATOSIS, SOLID TUMORS, IN-VIVO, INTRAABDOMINAL PRESSURE, MONOCLONAL-ANTIBODIES

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.21 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Lagast, Nick, Charlotte Carlier, and Wim Ceelen. 2018. “Pharmacokinetics and Tissue Transport of Intraperitoneal Chemotherapy.” Surgical Oncology Clinics of North America 27 (3): 477–494.
APA
Lagast, N., Carlier, C., & Ceelen, W. (2018). Pharmacokinetics and tissue transport of intraperitoneal chemotherapy. SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 27(3), 477–494.
Vancouver
1.
Lagast N, Carlier C, Ceelen W. Pharmacokinetics and tissue transport of intraperitoneal chemotherapy. SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA. 2018;27(3):477–94.
MLA
Lagast, Nick, Charlotte Carlier, and Wim Ceelen. “Pharmacokinetics and Tissue Transport of Intraperitoneal Chemotherapy.” SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA 27.3 (2018): 477–494. Print.
@article{8554619,
  abstract     = {The presence of a peritoneal barrier results in a pharmacokinetic advantage associated with intraperitoneal (IP) delivery of anticancer drugs. The anticancer efficacy of IP chemotherapy depends, however, on its ability to penetrate the tumor stroma. Tumor tissue transport is governed by diffusion and convection and is affected by numerous physical, biological, and pharmaceutical variables. From preclinical and clinical studies, it appears that tissue penetration after IP chemotherapy delivery is very limited. Several approaches are studied to improve tissue penetration of small molecular and macromolecular anticancer drugs after IP instillation.},
  author       = {Lagast, Nick and Carlier, Charlotte and Ceelen, Wim},
  issn         = {1055-3207},
  journal      = {SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA},
  language     = {eng},
  number       = {3},
  pages        = {477--494},
  title        = {Pharmacokinetics and tissue transport of intraperitoneal chemotherapy},
  url          = {http://dx.doi.org/10.1016/j.soc.2018.02.003},
  volume       = {27},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: